DNTH Dianthus Therapeutics, Inc. /DE/
Pharmaceutical Preparations · Nasdaq · SEC CIK 1690585 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.3%
TTM net income YoY-91.1%
TTM EPS YoY-64.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,739.3%
Net margin-7,973.3%
FCF margin-6,349.4%
EBITDA margin-8,733.9%
Returns
ROE-38.4%
ROA-35.9%
ROIC (approx.)-36.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets7.1%
Debt / equity0.00x
Current ratio13.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue10.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $284,000 | $396,000 | $193,000 | $1.16M | $1.33M |
| R&D expense | $45.60M | $48.69M | $34.53M | $59.90M | $32.49M | $26.25M | $27.00M | $26.41M |
| SG&A expense | $14.08M | $13.56M | $12.47M | $9.93M | $8.20M | $8.87M | $7.34M | $6.83M |
| Operating income | -$58.47M | -$61.48M | -$46.53M | -$69.54M | -$40.29M | -$34.93M | -$33.18M | -$31.92M |
| Net income | -$46.64M | -$50.22M | -$40.83M | -$64.43M | -$36.77M | -$31.63M | -$29.51M | -$28.44M |
| EBITDA | -$58.44M | -$61.45M | -$46.50M | -$69.51M | -$40.26M | -$34.90M | -$33.15M | -$31.89M |
| EPS (basic) | -0.81 | -0.90 | -0.85 | — | -0.97 | -0.88 | -0.82 | — |
| EPS (diluted) | -0.81 | -0.90 | -0.85 | — | -0.97 | -0.88 | -0.82 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 57.34M | 56.03M | 48.03M | — | 37.79M | 35.82M | 35.79M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.69M | $110.55M | $627.67M | $51.09M | $55.98M | $13.24M | $10.12M | $23.02M |
| Short-term investments | $782.10M | $776.26M | $483.59M | $353.21M | $346.63M | $244.15M | $253.11M | $252.45M |
| Receivables | $582,000 | $106,000 | $1.23M | $52,000 | $5.00M | $39,000 | $1.00M | $0 |
| Current assets | $856.04M | $897.54M | $1.12B | $409.44M | $413.82M | $263.61M | $271.00M | $280.90M |
| PP&E, net | $749,000 | $418,000 | $274,000 | $296,000 | $185,000 | $207,000 | $191,000 | $194,000 |
| Total assets | $1.28B | $1.21B | $1.25B | $530.92M | $577.45M | $326.08M | $348.58M | $374.01M |
| Current liabilities | $28.52M | $34.39M | $38.28M | $30.73M | $23.86M | $20.09M | $16.95M | $18.45M |
| Total liabilities | $34.82M | $41.25M | $45.57M | $37.52M | $30.99M | $23.00M | $19.97M | $21.53M |
| Shareholders' equity | $1.24B | $1.17B | $1.20B | $493.40M | $546.45M | $303.08M | $328.61M | $352.48M |
| Shares outstanding | 56.30M | 54.80M | 54.58M | 43.22M | 42.85M | 32.18M | 32.13M | 31.12M |
| Cash flow statement | ||||||||
| Operating cash flow | -$50.33M | -$48.98M | -$28.86M | -$46.98M | -$30.55M | -$23.89M | -$27.63M | -$27.44M |
| Capital expenditure | $368,000 | $181,000 | $10,000 | $138,000 | $5,000 | $46,000 | $24,000 | $31,000 |
| Free cash flow | -$50.70M | -$49.16M | -$28.87M | -$47.12M | -$30.56M | -$23.94M | -$27.65M | -$27.48M |
| Investing cash flow | -$111.87M | -$478.52M | -$133.97M | $37.20M | -$201.28M | $26.45M | $14.79M | -$23.11M |
| Financing cash flow | $107.47M | $10.38M | $739.41M | $4.88M | $274.51M | $568,000 | $161,000 | $39.68M |
| Depreciation & amortization | $37,000 | $37,000 | $32,000 | $27,000 | $27,000 | $30,000 | $27,000 | $26,000 |
| Stock-based compensation | $12.72M | $11.90M | $10.60M | $5.98M | $5.79M | $5.71M | $5.32M | $3.92M |
Free plan shows the latest 8 periods; Pro shows all 39 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.